Ontology highlight
ABSTRACT: Background
Linezolid has been prioritized for treating multidrug-resistant tuberculosis (MDR TB), but toxicity limits its use. We report treatment outcomes for MDR TB patients in California who received standard-dose linezolid vs those who switched to low-dose.Methods
We include culture-positive MDR TB cases treated with linezolid and receiving California MDR TB Service consultation during 2009-2016. Demographic, clinical, and laboratory data are analyzed using univariate analysis to compare patients who received linezolid of different dosing strategies. Analysis end points are linezolid treatment duration (measure of tolerability), treatment success (completion or cure), and adverse events (AEs).Results
Sixty-nine of 194 (36%) MDR TB patients met inclusion criteria
SUBMITTER: Mase A
PROVIDER: S-EPMC9801093 | biostudies-literature | 2022 Dec
REPOSITORIES: biostudies-literature